Update on immunotherapy in AML and MDS: Monoclonal antibodies and checkpoint inhibitors paving the road for clinical practice

Research output: Chapter in Book/Report/Conference proceedingChapter

16 Scopus citations

Abstract

In the past few years, our improved understanding of the pathogenesis of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) has led to remarkable advances in the development of novel therapeutic approaches for these diseases. This chapter summarizes the available clinical data with immune-based therapeutic modalities in AML and MDS, focusing on monoclonal antibodies, T cell engager antibodies, chimeric antigen receptor (CAR)-T cells, and checkpoint blockade via blockade of PD-1/PD-L1 or CTLA4. Numerous clinical trials are currently ongoing in patients with AML and MDS, both in the frontline and relapsed refractory setting. Given the natural diversity of AML blasts, it became apparent that the best responses would be achieved with rationally designed combination strategies of immune therapy, molecular therapy, and chemotherapy. A number of such combinations are enrolling patients with AML in various clinical settings. Biomarkers to select the optimal combination regimen for individual patients are critical.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages97-116
Number of pages20
DOIs
StatePublished - 2018

Publication series

NameAdvances in Experimental Medicine and Biology
Volume995
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Keywords

  • Acute myeloid leukemia
  • Immune checkpoint blockade
  • Immunotherapy
  • Monoclonal antibody

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Update on immunotherapy in AML and MDS: Monoclonal antibodies and checkpoint inhibitors paving the road for clinical practice'. Together they form a unique fingerprint.

Cite this